BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2383 related articles for article (PubMed ID: 25574681)

  • 41. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin.
    Mills G; Dahan MH
    Arch Gynecol Obstet; 2022 Nov; 306(5):1731-1737. PubMed ID: 35932297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
    Santos-Ribeiro S; Mackens S; Popovic-Todorovic B; Racca A; Polyzos NP; Van Landuyt L; Drakopoulos P; de Vos M; Tournaye H; Blockeel C
    Hum Reprod; 2020 Dec; 35(12):2808-2818. PubMed ID: 32964939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Luteal phase support for assisted reproduction cycles.
    van der Linden M; Buckingham K; Farquhar C; Kremer JA; Metwally M
    Cochrane Database Syst Rev; 2011 Oct; (10):CD009154. PubMed ID: 21975790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Withholding gonadotropins until human chorionic gonadotropin administration.
    Abdallah R; Kligman I; Davis O; Rosenwaks Z
    Semin Reprod Med; 2010 Nov; 28(6):486-92. PubMed ID: 21082507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
    Zhou C; Yang X; Wang Y; Xi J; Pan H; Wang M; Zhou Y; Xiao Y
    Hum Reprod; 2022 Jul; 37(8):1795-1805. PubMed ID: 35595223
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
    Itskovitz-Eldor J; Kol S; Mannaerts B
    Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
    Kol S; Homburg R; Alsbjerg B; Humaidan P
    Acta Obstet Gynecol Scand; 2012 Jun; 91(6):643-7. PubMed ID: 22428986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
    Abdulkhalikova D; Bokal EV; Stimpfel M; Ciglar P; Korosec S
    Front Endocrinol (Lausanne); 2022; 13():826411. PubMed ID: 35464066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ovarian stimulation for freeze-all IVF cycles: a systematic review.
    Mizrachi Y; Horowitz E; Farhi J; Raziel A; Weissman A
    Hum Reprod Update; 2020 Jan; 26(1):118-135. PubMed ID: 31867625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases.
    Gurbuz AS; Gode F; Ozcimen N; Isik AZ
    Reprod Biomed Online; 2014 Nov; 29(5):541-4. PubMed ID: 25246114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome.
    Fusi FM; Arnoldi M; Bosisio C; Lombardo G; Ferrario M; Zanga L; Galimberti A; Capitanio E
    Gynecol Endocrinol; 2015; 31(9):693-7. PubMed ID: 26527503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.
    Kadoura S; Alhalabi M; Nattouf AH
    Sci Rep; 2022 Mar; 12(1):4456. PubMed ID: 35292717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 120.